Enzon Pharmaceuticals, Inc.
ENZN
$0.06
$0.005.26%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 26.00K | 26.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 26.00K | 26.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | 0.00 | 26.00K | 26.00K |
| SG&A Expenses | 1.86M | 1.87M | 1.99M | 2.03M | 1.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.86M | 1.87M | 1.99M | 2.03M | 1.35M |
| Operating Income | -1.86M | -1.87M | -1.99M | -2.00M | -1.33M |
| Income Before Tax | -3.39M | -2.12M | -1.01M | 299.00K | 1.13M |
| Income Tax Expenses | 19.00K | 286.00K | 319.00K | 365.00K | 347.00K |
| Earnings from Continuing Operations | -3.41 | -2.41 | -1.33 | -0.07 | 0.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.41M | -2.41M | -1.33M | -66.00K | 778.00K |
| EBIT | -1.86M | -1.87M | -1.99M | -2.00M | -1.33M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.07 | -0.05 | -0.04 | -0.02 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| EPS Diluted | -0.08 | -0.05 | -0.04 | -0.02 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Average Basic Shares Outstanding | 296.86M | 296.86M | 296.86M | 296.86M | 296.86M |
| Average Diluted Shares Outstanding | 296.86M | 296.86M | 296.86M | 296.86M | 296.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -37.40% | -52.90% | -95.72% | -1,931.82% | 163.88% |